Innovative cancer med-tech, leveraging genomic, histological and clinico-demographic data to predict patient’s responses to cancer immunotherapy.
86% of minimum goal raised
Minimum Target £ 350,000 |
Minimum investment amount £ 10,000 |
Maximum Target £ 550,000 |
Maximum investment amount £ 550,000 |
Curenetics aims to optimise cancer treatment delivery by improving the prediction of immunotherapy treatment response, toxicity, and resistance through data-driven approaches. Our goal is to leverage clinical, genomic and histological biomarker data to develop predictive models of response to immunotherapy for cancers even before commencing treatment. We are backed by several clinical partners and advisors who work alongside us to provide us guidance and support to ensure our product has a good market fit. Our core team is made up of our CEO, CTO/data scientist, COO/AI engineer Operational and Clinical Lead and Immunologist who are working tirelessly to turn our mission into a reality
Curenetics at Angels Den's HealthTech Pitching Event
We will develop a fully tested and validated decision support tool for cancer immunotherapy response prediction for use by clinicians and allied medical professionals. The support tool will employ state-of-the-art machine learning methodologies for pre-processing of high dimensional genomic and imaging data, for the discovery of patterns or motifs related to cancer response and treatment toxicity. This tool will be offered as software as medical device(SaMD). In addition to the machine learning predictive tools, a user-friendly graphical user interface for the developed software tools will be made according to the specifications of existing medical software platforms and user specifications
The tool will aid clinicians in deciding the best immunotherapy treatment strategy for cancer patients. This will lead to better patient selection, improved patient survival, reduced treatment toxicity and value for money for healthcare providers. This will usher in the next level of personalised cancer care.
Our business model is software as a service or medical device (SaaS/SaMD) licensed to hospitals, healthcare providers and healthcare insurers around the world. We are currently focusing on cancer immunotherapy applications which is a huge market that is predicted to be worth over £300B by 2030. Beyond cancer, we will enter other markets such as gastroenterology, rheumatology and ophthalmology where immunotherapy treatment are increasingly used.
We will develop a fully tested and validated decision support tool for cancer immunotherapy response prediction for use by clinicians and allied medical professionals. The support tool will employ state-of-the-art machine learning methodologies for pre-processing of high dimensional genomic and imaging data, for the discovery of patterns or motifs related to cancer response and treatment toxicity. This tool will be offered as software as medical device(SaMD). In addition to the machine learning predictive tools, a user-friendly graphical user interface for the developed software tools will be made according to the specifications of existing medical software platforms and user specifications
The tool will aid clinicians in deciding the best immunotherapy treatment strategy for cancer patients. This will lead to better patient selection, improved patient survival, reduced treatment toxicity and value for money for healthcare providers. This will usher in the next level of personalised cancer care.
Our business model is software as a service or medical device (SaaS/SaMD) licensed to hospitals, healthcare providers and healthcare insurers around the world. We are currently focusing on cancer immunotherapy applications which is a huge market that is predicted to be worth over £300B by 2030. Beyond cancer, we will enter other markets such as gastroenterology, rheumatology and ophthalmology where immunotherapy treatment are increasingly used.